Sanofi Rises On Unusually High Volume (SNY)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Sanofi (NYSE: SNY) is trading at unusually high volume Friday with 7.6 million shares changing hands. It is currently at 4.6 times its average daily volume and trading up 95 cents (+2%) at $48.28 as of 4:03 p.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sanofi has a market cap of $129.14 billion and is part of the health care sector and drugs industry. Shares are up 3.1% year to date as of the close of trading on Thursday.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company has a P/E ratio of 26.3, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Sanofi Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe